Oral versus intravenous therapy in the treatment of systemic mycosis

Clinical Microbiology and Infection

Volumn 10, Issue SUPPL. 1, 2004, Pages 96-106

  Azanza Perea, J R ^a   Sadaba Diaz de Rada B ^a   Garcia Quetglas E ^a   Munoz Juarez M J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Antifungal therapy; Systemic mycosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; COST CONTROL; DRUG BIOAVAILABILITY; DRUG COST; HUMAN; IMMUNE DEFICIENCY; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; SYSTEMIC MYCOSIS;

EID: 1642290252     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1470-9465.2004.00846.x     Document Type: Article

References (129)

1. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogenic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
2. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
3. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 1998; 9: 136-46.
4. Castro J, Samore MH, Hadley S, Lewis HD, Jenkins RI, Karchmer AW. Development and validation of a prediction rule for invasive fungal infection in liver transplant recipients (Abstract J45a). In: 38th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, 1998; 464.
5. Singh N, Linden PK, Munoz P, Dominguez EA. Emerging trends in invasive mold infections in organ transplant recipients (Abstract 1327). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, 2000; 376.
6. Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-90. J Infect Dis 1993; 167: 1247-51.
7. Archibald LK, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates for inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-15.
8. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infectious Dis 1997; 24: 1122-8.
9. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981-93. Infect Cont Hospital Epid 1981; 18: 369-75.
10. Nguyen MH, Peacock JE Jr, Morris AJ et al. The changing face of candidemia: emergence on non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
11. Chandrasekar PH, Gatny CN and the Bone Marrow Transplant Team. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J Antimicrob Chemother 1994; 33: 309-18.
12. Wingard JR, Marz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Eng J Med 1991; 325: 1274-7.
13. Berrouane VF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a University hospital. J Clin Microbiol 1999; 37: 531-7.
14. Gleason TG, May AK, Caparelli D, Farr BM, Sawyer MD. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997; 132: 197-202.
15. Masia Canuto M, Gutierrez Rodero F, Ortiz de la Tabla Ducasse V et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2000; 19: 593-601.
16. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658-61.
17. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
18. Chapman SW, Bradsher RW Jr, Campbell GD Jr, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30: 679-83.
19. Kauffman CA, Hajjeh R. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000; 30: 684-7.
20. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688-95.
21. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
22. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-18.
23. Mann HJ, Fuhs DW, Cerra FB. Pharmacokinetics and pharmacodinamics in critically ill patients. World J Surg 1987; 11: 210-17.
24. Jellet LB, Heazlewood VJ. Pharmacokinetics in acute illness. Med J Aust 1990; 153: 534-41.
25. Labadie EI, Hamilton RH. Survival improvement in coccidioidal meningitis by high-dose inthrathecal amphotericin B. Arch Intern Med 1986; 146: 2013-18.
26. Galgiani JN, Cloud GA, Catanzaro A et al. Fluconazole (FLU) versus itroconazole (ITRA) for coccidioidomycosis: randomized, multicenter, double-blind trial in nonmeningeal progressive infections (abstract 100). Clin Infect Dis 1998; 27: 939.
27. Dewsnup DH, Galgiani JN, Graybill JR et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124: 305-10.
28. Edwards JE Jr, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
29. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
30. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2349-53.
31. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital. epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
32. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108: 88-100.
33. Walsh T, Whitcomb PO, Ravankar S, Shannon K, Alish S, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated episodes of neutropenia. Cancer 1995; 76: 2357-62.
34. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41.
35. Sobel JD, Kauffman CA, McKinsey D et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30: 19-24.
36. Walsh TJ, Gray W. Candida epiglottitis in immunocompromised patients. Chest 1987; 91: 482-5.
37. Wang JN, Liu CC, Huang TZ, Huang SS, Wu JM. Laryngeal candidiasis in children. Scand J Infect Dis 1997; 29: 427-9.
38. Almekinders LC, Greene WB. Vertebral Candida infections: a case report and review of the literature. Clin Orthop 1991; 267: 174-8.
39. Hennequin C, Bouree P, Hiesse C, Dupont B, Charpentier B. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis 1996; 23: 176-8.
40. Sugar AM, Saunders C, Diamond RD. Successful treatment of Candida osteomyelitis with fluconazole: a non-comparative study of two patients. Diagn Microbiol Infect Dis 1990; 13: 517-20.
41. Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 1986; 8: 309-21.
42. Michel C, Courdavault L, al Khayat R, Viron B, Roux P, Mignon F. Fungal peritonitis in patients on peritoneal dialysis. Am J Nephrol 1994; 14: 113-20.
43. Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-terms antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995; 60: 538-43.
44. Johnston P, Lee J, Demanski M et al. Late recurrent Candida endocarditis. Chest 1991; 99: 1531-3.
45. Baddour LM. Long-term suppressive therapy for Candida parapsilosis induced prosthetic valve endocarditis. Mayo Clin Proc 1995; 70: 773-5.
46. Schrank JH Jr, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 1995; 21: 182-7.
47. Berg RA, Stein JM. Medical management of fungal suppurative thrombosis of great central veins in a child. Pediatr Infect Dis J 1989; 8: 469-70.
48. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984; 6: 791-801.
49. Marr B, Gross S, Cunningham C, Weiner L. Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis 1994; 19: 795-6.
50. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989; 1: 746-8.
51. Powderly WG, Finkelstein DM, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700-5.
52. Chapman SW, Lin AC, Hendricks A et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997; 12: 219-28.
53. Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B. Am Rev Respir Dis 1969; 99: 895-902.
54. National Institute of Allergy and Infectious Diseases Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized trial. Ann Intern Med 1985; 103: 861-72.
55. Dismukes WE, Bradsher RW, Cloud GC et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489-97.
56. Pappas PG, Bradsher RW, Kauffman CA et al. Treatment of blastomycosis with higher dose fluconazole. Clin Infect Dis 1997; 25: 200-5.
57. Sharkey-Mathis PK, Kauffman CA, Braybill JR et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279-85.
58. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986; 65: 143-53.
59. Kauffman CA, Pappas PG, McKinsey DS et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22: 46-50.
60. Dismukes WE, Bradsher RW Jr, Cloud GC et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group Am J Med 1992; 93: 489-97.
61. Dismukes WE, Cloud G, Bowles C et al. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985; 103: 861-72.
62. Slama TG. Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole. Am J Med 1983; 74: 70-3.
63. McKinsey DS, Kauffman CA, Pappas PG et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23: 996-1001.
64. Reddy PA, Gorelick DF, Brasher CA, Larsh H. Progressive disseminated histoplasmosis as seen in adults. Am J Med 1970; 48: 629-36.
65. Sarosi GA, Voth DW, Dahl BA, Doto IL, Tosh FE. Disseminated histoplasmosis: results of long-term follow-up. Ann Intern Med 1971; 75: 511-16.
66. Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system: a clinical review. Medicine (Baltimore) 1990; 69: 244-60.
67. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Arch Intern Med 1971; 128: 541-5.
68. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5: 1985-93.
69. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147-201.
70. Denning D, del Favero A, Gluckman E et al. The efficacy and tolerability of UK-109,496 (voriconazole) in the treatment of invasive aspergillosis (abstract P552). In: Proceedings of the 13th Congress of the International Society for Human and Animal Mycology (Parma, Italy). Salsomaggiote Terme. Italy: International Society for Human and Animal Mycology. 1997; 217.
71. Verweij PE, Brikman K, Kremer HPH, Kullberg BJ, Meis JFGM. Aspergillus meningitis: diagnosis by nonculture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186-9.
72. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal menningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317: 334-41.
73. Dromer F, Mathoulin S, Dupont B et al. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 1996; 22: S154-S160.
74. Pappas PG, Perfect J, Larsen RA et al. Cryptococcosis in HIV-negative patients: analysis of 306 cases (abstract 101). Clin Infect Dis 1998; 27: 939.
75. Jones B, Larsen RA, Forthal D, Haghighat D, Bozzette S. Treatment of nonmeningeal cryptococcal disease in HIV-infected persons (abstract F4). In: Proceedings of the 91st Annual Meeting of the American Society of Microbiology (Dallas, TX). Washington, DC. American Society for Microbiology, 1991.
76. Saag MS, Cloud GC, Craybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 291-6.
77. Bennett JE, Dismukes W, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-31.
78. Van der Horst C, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
79. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992; 326: 83-9.
80. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK0991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
81. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998; 42: 313-18.
82. Oakely KL, Moore CB, Denning DW. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998; 42: 91-4.
83. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole and amphotericin B. Diagn Microbiol Infect Dis 1998; 33: 7-11.
84. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 1997; 41: 841-3.
85. Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
86. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species. Antimicrob Agents Chemother 2000; 44: 441-3.
87. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CRJ, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41: 1832-4.
88. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
89. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44: 1734-6.
90. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998; 42: 161-3.
91. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-2.
92. Pfaller MA, Messer SA, Hollis RJ et al, In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42: 3242-4.
93. Rex JH, Pfaller MA, Barry AL et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-4.
94. Barchiesi FB, Arzeni D, Fothergill AW et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44: 226-9.
95. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant Candida isolates. In vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998; 42: 253-6.
96. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 2883-6.
97. Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to voriconazole, terbinafine, ketoconazole and itraconazole (Abstract J-17). In: 38th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, 1998; 455.
98. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-6.
99. Patterson BE, Coates PE. UK-109,496, a novel, widespread triazole derivate for the treatment of fungal infections: Pharmacokinetics in man (Abstract F-78). In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 1995; 126.
100. Blummer JL, Yanovitch S, Schlamm H, Romero A. Pharmacokinetics (PK) and safety of oral voriconazole (V) in patients at risk of fungal infections: a dose escalation study (Abstract A-15). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2001; 3.
101. Purkins L, Kleinermans D, Greenhalgh K et al. The effect of food on voriconazole pharmacokinetics (Abstract P-88). In: 4th Trends in Invasive Fungal Infections, Barcelona Spain, 1994.
102. Patterson BE, Roffey S, Jezequel SG, Jones B. UK-109,496, a novel, wide-spread triazole derivate for the treatment of fungal infections: Disposition in man (Abstract F-79). In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 1995; 126.
103. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-5.
104. Werweij PE, Den Bergh MF, Rath PM, De Pauw BE, Voss AM. Invasive Aspergillosis caused by Aspergillus ustus. Case report and review. J Clin Microb 1999; 37: 1606-9.
105. Hoepelman AIM, Hodges MR, Lutsar I. Cerebral aspergilsis and scedosporinosis: voriconazole. A new treatment option for children with life-threattening cerebral fungal infection. In: 18th European Society of Pediatrics Infectious Disease, Noordwijk, 2000.
106. Nesky MA, McDougal CC, Peacock J. Pseudoallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage. case report and review of CNS pseudoallescheriasis. In: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, 2000.
107. Tomaszewski K, Purkins L. The pharmacokinetics (PK) and safety of sulphobutylether-b-cyclodextrin (SBECD) (Abstract A-23). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago IL, 2001.
108. Tan KKC, Wood N, Weil A. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment (Abstract A-16). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago IL, 2001.
109. Walsh TJ, Arguedas A, Driscoll T et al. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration (Abstract A-17). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001.
110. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of omeprazole (Abstract A-19). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001.
111. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus (Abstract A-20). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001.
112. Tan KKC, Brayshaw N, Oakes M. Investigation of the relationship between plasma voriconazole (V) concentrations and liver function test (LFT) abnormalities in therapeutic trials (Abstract A-18). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001.
113. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole (Poster - Abstract A-844). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 23.
114. Purkins L, Kleinermans D, Greenhalgh K et al. Rifampicin and rifabutin markedly reduce plasma voriconazole concentrations (Abstract P-87). In: 4th Trends in Invasive Fungal Infections, Barcelona Spain, 1997.
115. Ghahramani P, Wood ND, Kleinermans D, Love ER. No significant pharmacokinetic interactions between voriconazole and indinavir (Poster - Abstract A-848). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 24.
116. Ghahramani P, Purkins L, Wood ND, Love ER, Eve MD, Fielding A. Drug interactions between voriconazole and phenytoin (Poster - Abstract A-847). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 24.
117. Ghahramani P, Purkins L, Kleinermans D, Wood ND, Nichols DJ. Voriconazole potentiates warfarin-induced prolongation of prothrombin time (Poster - Abstract A-846). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 24.
118. Ghahramani P, Purkins L, Kleinermans D, Wood ND, Nichols DJ. Voriconazole does not affect the pharmacokinetics of digoxin (Poster - Abstract A-849). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 25.
119. Ghahramani P, Romero AJ, Lant AF, Allen MJ. Effect of voriconazole on the pharmacokinetics of cyclosporin (Poster - Abstract A-845). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 24.
120. Ghahramani P, Purkins L, Kleinermans D, Nichols DJ. Effect of omeprazole on the pharmacokinetics of voriconazole (Poster - Abstract A-843). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 23.
121. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
122. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
123. Dening DW, del Favero A, Gluckman E et al. UK-109,496 A novel wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis.. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; Abstact F80.
124. Dening DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
125. Mouas H, Lortholary O, Alexandre M et al. Aspergillus fumigatus spondylodiscitis successfully treated by voriconazole in a non-immunocompromised patient. In: 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, 2001.
126. Torre cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, 2000.
127. Muñoz P, Marin M, Tornero P, Martín Rabadán P, Rodríguez-Creixéms M, Bouza E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31: 1499-501.
128. Perfect J, Lutsar I, González-Ruiz A. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, 2000.
129. Walsh TJ, Lutsar I, Ghahramani P, Hodges MR. Efficacy and safety of voriconazole (VORI) in the treatment of invasive fungal infection in children (Abstract A-1110). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society of Microbiology, 2000; 372.